By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Veteran financial expert Stacy Johnson shares a five-point strategy for navigating market downturns, emphasizing maintaining ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Delhi High Court bars Dr Reddy's and OneSource from selling semaglutide in India, supporting Novo Nordisk's patent rights as ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

Dr Reddy's CFO Narasimham recently told to Moneycontrol he is confident of 'sustained double-digit sales growth' in FY26, ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

UnitedHealth Group (NYSE:UNH) has faced severe headwinds in 2025, with its stock plummeting over 50% from its April high.

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...